| Nicholas J Olson, MD | |
|
1111 Duff Avenue, Ames, IA 50010-3014 | |
| (515) 239-2411 | |
| (515) 956-2714 |
| Full Name | Nicholas J Olson |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 11 Years |
| Location | 1111 Duff Avenue, Ames, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558704338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | MD45567 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Greeley Medical Center | Ames, IA | Hospital |
| Centracare Health - Monticello | Monticello, MN | Hospital |
| Carris Health Llc | Willmar, MN | Hospital |
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Trinity Regional Medical Center | Fort dodge, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carris Health Llc | 7012274228 | 40 |
| St Cloud Hospital | 4880594779 | 188 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20060504000839 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | St Cloud Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043269798 PECOS PAC ID: 4880594779 Enrollment ID: O20110221000134 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275872772 PECOS PAC ID: 3870739410 Enrollment ID: O20130426000215 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558600874 PECOS PAC ID: 3870739410 Enrollment ID: O20130515000683 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Entity Name | Carris Health Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1134632680 PECOS PAC ID: 7012274228 Enrollment ID: O20180111000831 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas J Olson, MD 1215 Duff Avenue, Ames, IA 50010-3014 Ph: (515) 239-2411 | Nicholas J Olson, MD 1111 Duff Avenue, Ames, IA 50010-3014 Ph: (515) 239-2411 |
News Archive
Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
After telling the Associated Press that he didn't think a repeal of the health law was going to happen, Ohio Gov. John Kasich, a Republican, took aggressive steps to attempt to correct the record. His statement, he said, was meant only about attempts to repeal the Medicaid expansion, which Ohio has implemented.
Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.
People with blood type O often get more severely ill from cholera than people of other blood types. New research from Washington University School of Medicine in St. Louis may explain why.
Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
› Verified 8 days ago
Dr. Nima Ahmad Golchin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Duff Ave, Ames, IA 50010 Phone: 515-239-4456 Fax: 515-239-4761 | |
John George Hardie, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Avenue, Ames, IA 50010 Phone: 515-239-2411 Fax: 515-956-2714 | |
David S. Sosnouski, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Duff Avenue, Ames, IA 50010 Phone: 515-239-4456 Fax: 515-239-4761 | |
Dr. Lyman Shane Hopkins, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-2411 Fax: 515-956-2714 | |
Dr. John Dee Shierholz, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1215 Duff Ave, Ames, IA 50010 Phone: 515-239-4456 Fax: 515-239-4761 | |
Dr. Douglas R. Lake, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Duff Avenue, Ames, IA 50010 Phone: 515-239-4456 Fax: 515-239-4761 | |
Dean C. Gute, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Mcfarland Clinkc, Pc, 1215 Duff Ave, Ames, IA 50010 Phone: 515-239-4456 Fax: 515-239-4761 |